Hodgkin Lymphoma

Chapter
First Online:
Part of the Contemporary Hematology book series (CH)

Abstract/Scope of Chapter

This chapter covers the clinical features, classification, differential diagnosis, and pathogenesis of Hodgkin lymphoma. Differences between the histogenesis and appearance of classical subtypes (nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted) and the nodular lymphocyte predominant type are covered.

Keywords

Hodgkin lymphoma Reed-Sternberg (R-S) cell Hodgkin lymphoma, L&H (lymphocytic/histiocytic) cell Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) Hodgkin lymphoma, classical type (CHL) Hodgkin lymphoma, nodular sclerosis type (NSCHL) Hodgkin lymphoma, mixed cellularity (MCCHL) Hodgkin lymphoma, lymphocyte rich (LRHL) Hodgkin lymphoma, lymphocyte depleted (LDHL) Epstein-Barr Virus (EBV), Hodgkin lymphoma, CD15 Hodgkin lymphoma, CD30 Hodgkin lymphoma, progressive transformation of germinal centers (PTGC) T-cell/histiocyte-rich B-cell lymphoma (TCHRBCL), differential with Hodgkin lymphoma Anaplastic large cell lymphoma (ALCL), differential with Hodgkin lymphoma Primary mediastinal large B-cell lymphoma (PMLBCL), differential with Hodgkin lymphoma Grey zone lymphoma 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Khan G. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin’s lymphoma? Exp Hematol 2006;34:399-406.PubMedCrossRefGoogle Scholar
  2. 2.
    Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumour of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2008.Google Scholar
  3. 3.
    Hummel M. World Health Organization and beyond: new aspects in the pathology of an old disease. Hematol Oncol Clin North Am 2007;21:769-86.PubMedCrossRefGoogle Scholar
  4. 4.
    Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A 1994;91:10962-6.PubMedCrossRefGoogle Scholar
  5. 5.
    Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin’s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996;184:1495-505.PubMedCrossRefGoogle Scholar
  6. 6.
    Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 2001;97:496-501.PubMedCrossRefGoogle Scholar
  7. 7.
    Marafioti T, Hummel M, Foss HD, et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000;95:1443-50.PubMedGoogle Scholar
  8. 8.
    Chang KC, Khen NT, Jones D, Su IJ. Epstein-Barr virus is associated with all histological subtypes of Hodgkin lymphoma in Vietnamese children with special emphasis on the entity of lymphocyte predominance subtype. Hum Pathol 2005;36:747-55.PubMedCrossRefGoogle Scholar
  9. 9.
    Chang KC, Huang GC, Jones D, Tsao CJ, Lee JY, Su IJ. Distribution and prognosis of WHO lymphoma subtypes in Taiwan reveals a low incidence of germinal-center derived tumors. Leuk Lymphoma 2004;45:1375-84.PubMedCrossRefGoogle Scholar
  10. 10.
    Nakatsuka S, Aozasa K. Epidemiology and pathologic features of Hodgkin lymphoma. Int J Hematol 2006;83:391-7.PubMedCrossRefGoogle Scholar
  11. 11.
    Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008;26:434-9.PubMedCrossRefGoogle Scholar
  12. 12.
    Boudova L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 2003;102:3753-8.PubMedCrossRefGoogle Scholar
  13. 13.
    Lin P, Medeiros LJ, Wilder RB, Abruzzo LV, Manning JT, Jones D. The activation profile of tumour-associated reactive T-cells differs in the nodular and diffuse patterns of lymphocyte predominant Hodgkin’s disease. Histopathology 2004;44:561-9.PubMedCrossRefGoogle Scholar
  14. 14.
    Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003;27:1346-56.PubMedCrossRefGoogle Scholar
  15. 15.
    Jones D. Dismantling the germinal center: comparing the processes of transformation, regression, and fragmentation of the lymphoid follicle. Adv Anat Pathol 2002;9:129-38.PubMedCrossRefGoogle Scholar
  16. 16.
    Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C. Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features. Histopathology 2002;40:31-45.PubMedCrossRefGoogle Scholar
  17. 17.
    Khoury JD, Jones D, Yared MA, et al. Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol 2004;28:489-95.PubMedCrossRefGoogle Scholar
  18. 18.
    Anagnostopoulos I, Hansmann ML, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000;96:1889-99.PubMedGoogle Scholar
  19. 19.
    Hsi ED. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Leuk Lymphoma 2008;49:1668-80.PubMedCrossRefGoogle Scholar
  20. 20.
    Diehl V, Behringer K. Could BEACOPP be the new standard for the treatment of advanced Hodgkin’s lymphoma (HL)? Cancer Invest 2006;24:713-7.PubMedCrossRefGoogle Scholar
  21. 21.
    Pileri SA, Ascani S, Leoncini L, et al. Hodgkin’s lymphoma: the pathologist’s viewpoint. J Clin Pathol 2002;55:162-76.PubMedCrossRefGoogle Scholar
  22. 22.
    MacLennan KA, Bennett MH, Tu A, et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin’s disease. A study of 1659 patients. Cancer 1989;64:1686-93.PubMedCrossRefGoogle Scholar
  23. 23.
    von Wasielewski S, Franklin J, Fischer R, et al. Nodular sclerosing Hodgkin disease: new grading predicts prognosis in intermediate and advanced stages. Blood 2003;101:4063-9.CrossRefGoogle Scholar
  24. 24.
    Patsouris E, Noel H, Lennert K. Cytohistologic and immunohistochemical findings in Hodgkin’s disease, mixed cellularity type, with a high content of epithelioid cells. Am J Surg Pathol 1989;13:1014-22.PubMedCrossRefGoogle Scholar
  25. 25.
    Martin-Subero JI, Gesk S, Harder L, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 2002;99:1474-7.PubMedCrossRefGoogle Scholar
  26. 26.
    Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin’s disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 1999;18:3063-70.PubMedCrossRefGoogle Scholar
  27. 27.
    Emmerich F, Theurich S, Hummel M, et al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol 2003;201:413-20.PubMedCrossRefGoogle Scholar
  28. 28.
    Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995;80:389-99.PubMedCrossRefGoogle Scholar
  29. 29.
    Mathas S, Lietz A, Anagnostopoulos I, et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004;199:1041-52.PubMedCrossRefGoogle Scholar
  30. 30.
    Kuppers R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer 2009;9:15-27.PubMedCrossRefGoogle Scholar
  31. 31.
    Lee SS, Ryoo BY, Park YH, et al. Hodgkin lymphoma with unusual intrasinusoidal pattern of infiltration. Leuk Lymphoma 2004;45:2135-41.PubMedCrossRefGoogle Scholar
  32. 32.
    Gorczyca W, Tsang P, Liu Z, et al. CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis. Int J Oncol 2003;22:319-24.PubMedGoogle Scholar
  33. 33.
    Bonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood 2004;104:3358-60.PubMedCrossRefGoogle Scholar
  34. 34.
    Tan BT, Seo K, Warnke RA, Arber DA. The frequency of immunoglobulin heavy chain gene and T-cell receptor gamma-chain gene rearrangements and Epstein-Barr virus in ALK+ and ALK- anaplastic large cell lymphoma and other peripheral T-cell lymphomas. J Mol Diagn 2008;10:502-12.PubMedCrossRefGoogle Scholar
  35. 35.
    Herling M, Rassidakis GZ, Jones D, Schmitt-Graeff A, Sarris AH, Medeiros LJ. Absence of Epstein-Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria. Hum Pathol 2004;35:455-9.PubMedCrossRefGoogle Scholar
  36. 36.
    Maheswaran PR, Ramsay AD, Norton AJ, Roche WR. Hodgkin’s disease presenting with the histological features of Castleman’s disease. Histopathology 1991;18:249-53.PubMedCrossRefGoogle Scholar
  37. 37.
    Petrella T, Yaziji N, Collin F, et al. Implication of the Epstein-Barr virus in the progression of chronic lymphocytic leukaemia/small lymphocytic lymphoma to Hodgkin-like lymphomas. Anticancer Res 1997;17:3907-13.PubMedGoogle Scholar
  38. 38.
    Momose H. Jaffe ES, Shin SS, Chen YY. Weiss LM. Chronic lymphocytic leukemia/small lymphocytic lymphoma with Reed-Sternberg-like cells and possible transformation to Hodgkin’s disease. Mediation by Epstein-Barr virus. Am J Surg Pathol 1992;16:859-67.Google Scholar
  39. 39.
    Abruzzo LV, Rosales CM, Medeiros LJ, et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 2002;26:630-6.PubMedCrossRefGoogle Scholar
  40. 40.
    Higgins JP, van de Rijn M, Jones CD, Zehnder JL, Warnke RA. Peripheral T-cell lymphoma complicated by a proliferation of large B cells. Am J Clin Pathol 2000;114:236-47.PubMedCrossRefGoogle Scholar
  41. 41.
    Hasenclever D, Diehl VA. prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998;339:1506-14.Google Scholar
  42. 42.
    Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-52.PubMedCrossRefGoogle Scholar
  43. 43.
    Parkin DM, Whelan SL, Ferlay J, Storm H. Cancer Incidence in Five Continents. Vol I to VIII IARC CancerBase. Lyon: IARC Press, 2005:45-173.Google Scholar
  44. 44.
    Benharroch D, Levy A, Gopas J, Sacks M. Lymphocyte-depleted classic Hodgkin lymphoma-a neglected entity? Virchows Arch 2008;453:611-6.PubMedCrossRefGoogle Scholar
  45. 45.
    Garcia-Cosio M, Santon A, Martin P, et al. Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin’s lymphoma. Mod Pathol 2004;17:1531-8.PubMedCrossRefGoogle Scholar
  46. 46.
    Marafioti T, Mancini C, Ascani S, et al. Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin’s disease. Haematologica 2004;89:957-64.PubMedGoogle Scholar
  47. 47.
    McCune RC, Syrbu SI, Vasef MA. Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin’s and non-Hodgkin’s lymphomas: a comparative study using high throughput tissue microarrays. Mod Pathol 2006;19:1010-8.PubMedCrossRefGoogle Scholar
  48. 48.
    Niitsu N, Okamoto M, Tomita N, et al. Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin’s lymphoma. Leuk Lymphoma 2006;47:1908-14.PubMedCrossRefGoogle Scholar
  49. 49.
    Tamaru J, Tokuhira M, Nittsu N, et al. Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma. Leuk Lymphoma 2007;48:1127-38.PubMedCrossRefGoogle Scholar
  50. 50.
    Tzankov A, Zimpfer A, Pehrs AC, et al. Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol 2003;16:1141-7.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of PathologyNew York University Medical CenterNew YorkUSA

Personalised recommendations